RZBC Produces 100% of IVD Reagents in U.S., Mitigating Tariff Impact
18 April 2025 · Uncategorized ·
Source: · https://finance.technews.tw/2025/04/06/ivd-test-reagents/
The United States’ equal tariff policy has disrupted global supply chains, prompting biotechnology and healthcare companies to develop innovative strategies. ABC-KY's leading digital bio-barcode technology company, RZBC, announced today that since its founding in 2008, both its headquarters and manufacturing bases have been located in Los Angeles, California. Consequently, all of RZBC’s IVD reagents are produced within the United States, shielding them from tariff impacts.
RZBC stated that currently over ninety percent of their revenue comes from the U.S. market, with all IVD reagents manufactured domestically. This allows them to maintain stable production and sales operations compared to international competitors like Roche (Switzerland) or Diasorin (Italy), which rely on imports for multiple product lines and may face increased cost pressures due to tariffs.
RZBC further emphasized that this situation has strengthened their competitive advantage in the market. Their respiratory molecular reagents (RPP) have gained traction with several large flu testing laboratories, experiencing rapid demand growth approaching levels previously seen with its flagship gastrointestinal molecular reagent product (GPP).
Given the larger scale of the respiratory diagnostics market compared to gastroenteric pathogens and increasing laboratory customer demands for influenza tests, RZBC anticipates that their Respiratory Pathogen Panel (RPP) will soon match the performance of its Gastrointestinal Pathogen Panel (GPP), establishing them as dual core products within their IVD reagent portfolio.
Looking ahead to operations in the second half of this year, RZBC expects more national laboratories to complete product evaluations and transition into formal procurement processes. This is projected to significantly increase demand for both gastrointestinal (GPP) and respiratory (RPP) multi-molecular testing agents, driving strong performance momentum and further solidifying its leading position within the global IVD reagent market.
RZBC stated that currently over ninety percent of their revenue comes from the U.S. market, with all IVD reagents manufactured domestically. This allows them to maintain stable production and sales operations compared to international competitors like Roche (Switzerland) or Diasorin (Italy), which rely on imports for multiple product lines and may face increased cost pressures due to tariffs.
RZBC further emphasized that this situation has strengthened their competitive advantage in the market. Their respiratory molecular reagents (RPP) have gained traction with several large flu testing laboratories, experiencing rapid demand growth approaching levels previously seen with its flagship gastrointestinal molecular reagent product (GPP).
Given the larger scale of the respiratory diagnostics market compared to gastroenteric pathogens and increasing laboratory customer demands for influenza tests, RZBC anticipates that their Respiratory Pathogen Panel (RPP) will soon match the performance of its Gastrointestinal Pathogen Panel (GPP), establishing them as dual core products within their IVD reagent portfolio.
Looking ahead to operations in the second half of this year, RZBC expects more national laboratories to complete product evaluations and transition into formal procurement processes. This is projected to significantly increase demand for both gastrointestinal (GPP) and respiratory (RPP) multi-molecular testing agents, driving strong performance momentum and further solidifying its leading position within the global IVD reagent market.